NCT05371288

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)	Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Timeline

• Start date: 2025-06-01
• Primary completion: 2025-09-01
• Completion: 2025-11-01
• First posted: 2022-05-12
• Last updated: 2024-11-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study